AFT Pharmaceuticals has released Maxigesic®, a new analgesic tablet which for the first time in NZ combines Paracetamol and the anti-inflammatory Ibuprofen to provide superior pain relief to patients than either agent on its own.
AFT will supply Maxigesic® in NZ and Australia and is looking for a partner to sell the drug overseas. The global pain relief market is worth $27 billion a year and group CEO Dr Hartley Atkinson sees massive potential for this product to take a good share of that.
November 28, 2025
AFT Pharmaceuticals SA (Pty) Ltd (‘AFT SA’) announces it has successfully completed the acquisition of the Hospital Division business of Pharma Dy…
November 20, 2025
AFT Pharmaceuticals (NZX: AFT, ASX: AFP) today reports a strong first-half performance for the six months to 30 September 2025, with revenue growing 3…
November 12, 2025
AFT Pharmaceuticals has launched its full Lipo-Sachets® range in the U.S., featuring advanced collagen and vitamin supplements powered by patented LI…